- Home
- RM vs CNTX Comparison
RM vs CNTX Comparison
Compare RM & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RM | CNTX |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United States |
| Employees | 2112 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 334.1M | 283.9M |
| IPO Year | 2011 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RM | CNTX |
|---|---|---|
| Price | $37.21 | $2.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $30.00 | $6.60 |
| AVG Volume (30 Days) | 43.9K | ★ 628.3K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.12% | N/A |
| EPS Growth | 7.49 | ★ 17.39 |
| EPS | ★ 1.18 | N/A |
| Revenue | ★ $645,598,000.00 | N/A |
| Revenue This Year | $12.94 | N/A |
| Revenue Next Year | $8.97 | N/A |
| P/E Ratio | $30.64 | ★ N/A |
| Revenue Growth | ★ 9.70 | N/A |
| 52 Week Low | $26.06 | $0.52 |
| 52 Week High | $46.00 | $3.62 |
Technical Indicators
Market Signals| Indicator | RM | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.98 | 59.93 |
| Support Level | $35.98 | $2.74 |
| Resistance Level | $41.21 | $2.90 |
| Average True Range (ATR) | 1.14 | 0.17 |
| MACD | 0.24 | 0.07 |
| Stochastic Oscillator | 93.41 | 65.70 |
Price Performance
Historical ComparisonAbout RM Regional Management Corp.
Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. The company is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.